Retatrutide vs 5-Amino-1MQ
Retatrutide (LY3437943) is an investigational single peptide that activates the GIP, GLP-1 and glucagon receptors, and its literature runs from rodent pharmacology through phase 2 trials in obesity, type 2 diabetes and metabolic dysfunction-associated steatotic liver disease to a first phase 3 readout published in 2026. 5-Amino-1MQ is a cell-permeable small-molecule inhibitor of nicotinamide N-methyltransferase, the enzyme that methylates nicotinamide and thereby consumes S-adenosylmethionine while diverting nicotinamide away from NAD+ salvage; its efficacy record is entirely rodent and in vitro. The two are set side by side because both are promoted for fat loss, but no published study has administered, tested or even discussed them together. Searches of PubMed by title and abstract and of Europe PMC across full text returned no record naming both compounds. Any comparison is therefore assembled from two separate evidence bases that differ in species, endpoint, design and maturity, and the gap in maturity is the largest single fact about the pair.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has administered retatrutide and 5-Amino-1MQ within one experiment, and no publication of any kind names both compounds. Searches were run against PubMed by title and abstract and against Europe PMC across full text, using the alternate designations LY3437943 and 5-amino-1-methylquinolinium and the target name nicotinamide N-methyltransferase, and returned no shared record; the same searches also found no paper naming retatrutide alongside any NNMT inhibitor. Because no publication engages both, there is nothing to report even at the level of a review, an analytical method or a discussion. The comparison below is therefore indirect throughout. It sets a compound with completed randomised human trials and one published phase 3 result against a compound whose entire efficacy record consists of rodent models and enzyme kinetics, and the two literatures share no common endpoint, species, comparator or measurement method.
Side by side.
| Retatrutide | 5-Amino-1MQ | |
|---|---|---|
| Evidence maturity | Clinical | Preclinical only |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 13 | 8 |
| Newest paper | 2026 | 2026 |
| Molecular class and origin | A synthetic single-chain peptide engineered to act as a balanced agonist at three receptors that normally respond to separate endogenous hormones: GIP, GLP-1 and glucagon. | A synthetic quinolinium small molecule rather than a peptide. It inhibits an endogenous methyltransferase and does not act as an agonist at any receptor. |
| Mechanism as described in the literature | Receptor pharmacology reported balanced agonism at the glucagon, GIP and GLP-1 receptors, with the weight effect in obese rodents attributed to both reduced calorie intake and increased energy expenditure. | Inhibition of nicotinamide N-methyltransferase, which in rodent work raised adipose NAD+, suppressed lipogenic gene expression and altered polyamine flux. The 2014 Nature knockdown study that established the target reported increased energy expenditure without altered food intake. |
| Size of the evidence base | Fifteen studies in this library, most of them randomised controlled human trials, spanning phase 1b, phase 2, phase 2a and phase 3 designs plus two systematic reviews. | Fifteen studies in this library, none of them human. The set consists of rodent in vivo experiments, enzyme kinetics and narrative reviews of the target. |
| Best-characterised finding | In a 48-week phase 2 obesity trial the least-squares mean change in body weight at the highest dose group was -24.2% compared with -2.1% on placebo, and a phase 2a substudy reported relative liver fat reductions reaching -82.4% versus +0.3% on placebo. | Reversal of diet-induced obesity in mice: systemic administration reduced body weight and adiposity without reducing food intake, and a separate dose-ranging mouse study reported dose-dependent weight reduction with improved glucose tolerance and liver histopathology. |
| Human data | Extensive. Randomised, double-blind, placebo-controlled trials in type 2 diabetes and obesity, a placebo- and dulaglutide-controlled phase 2 trial, a MASLD substudy, body-composition and kidney-parameter analyses, and a published phase 3 readout in type 2 diabetes. | None. No human clinical trial of 5-Amino-1MQ has been reported in the peer-reviewed literature, and human pharmacokinetics, oral bioavailability, safety and target engagement are uncharacterised. |
| Evidence maturity | Clinical. A registrational phase 3 programme has been described in design papers and the first phase 3 result has been published, although the obesity, sleep apnoea and osteoarthritis trials had released rationale and design only. | Preclinical only. A 2026 review in Trends in Pharmacological Sciences framed clinical translation of NNMT inhibitors as an emerging prospect rather than an established one. |
| Safety signals reported | Adverse events across the phase 2 programme were predominantly gastrointestinal and dose-related. Long-term safety, cardiovascular outcomes and durability after discontinuation have not been established in peer-reviewed reports. | No human safety data exist. Unresolved preclinical questions include the long-term consequences of sustained NNMT inhibition for methylation potential, polyamine metabolism and tumour biology. |
| Regulatory status | Investigational and unapproved in every jurisdiction as of August 2026, with efficacy results for the phase 3 obesity programme disclosed by the sponsor as topline announcements rather than peer-reviewed publications. | No approved product, and no registered clinical trial identified in the peer-reviewed record. The compound appears in the literature only as a research tool for interrogating NNMT. |
And what it does not.
These two compounds sit at opposite ends of the evidence spectrum, and nothing published connects them. Retatrutide has been tested in randomised, placebo-controlled human trials across obesity, type 2 diabetes and steatotic liver disease, with a phase 3 readout in print and a registrational programme under way; what remains unestablished is long-term safety, cardiovascular outcomes and durability of effect after discontinuation. 5-Amino-1MQ has a coherent and independently replicated rodent story built on a validated molecular target, but no human participant has been dosed with it in the published literature, so human exposure, safety and target engagement are unknown. Material that presents the two as alternatives for the same purpose is setting a phase 3 investigational medicine against a preclinical research chemical. Neither is an approved treatment. The honest reading is that the retatrutide literature supports weight and metabolic effects in humans under trial conditions, while the 5-Amino-1MQ literature supports a hypothesis that has never been tested in people.
Common questions.
- Has any experiment tested retatrutide and 5-Amino-1MQ against each other?
No. Searches of PubMed by title and abstract and of Europe PMC across full text, run with the alternate names LY3437943 and 5-amino-1-methylquinolinium as well as the target name nicotinamide N-methyltransferase, returned no publication naming both compounds. That absence covers reviews and analytical papers as well as experiments, so there is no comparative reading of any kind to report. Every difference described on this page is drawn from two separate literatures rather than from a shared study design.
- Why is one described as clinical and the other as preclinical when both are promoted for body fat?
The labels describe study designs rather than intentions. Retatrutide has been evaluated in randomised, double-blind, placebo-controlled trials in humans, including a published phase 3 trial in type 2 diabetes, so its effects have been measured against placebo in people. 5-Amino-1MQ has only been given to rodents or applied to cells and enzymes, and the reported reductions in body weight and adiposity are mouse findings. Sharing a therapeutic aim does not make two evidence bases comparable in quality or in what they can support.
- Does the NNMT target have any independent validation?
Yes, at the preclinical level. A 2014 Nature report showed that antisense knockdown of NNMT in adipose tissue and liver protected mice against diet-induced obesity, and separate groups have since reproduced the pharmacology with chemically distinct inhibitors, including a tricyclic series and the compound JBSNF-000088, which lowered tissue 1-methylnicotinamide and normalised glucose tolerance in obese rodents. Validation of that kind establishes the biology of the enzyme rather than the clinical usefulness of any inhibitor in humans.
- What does the retatrutide literature not yet establish?
Several things. As of August 2026 the compound remained investigational and unapproved, and long-term safety, cardiovascular outcome data and durability of effect after discontinuation had not been established in peer-reviewed reports. The TRIUMPH phase 3 obesity, sleep apnoea and osteoarthritis trials had published rationale and design papers only, with efficacy disclosed as sponsor topline announcements. The published results also describe supervised trial conditions with structured dose escalation, and adverse events were predominantly gastrointestinal and dose-related.
- Are the reported mechanisms related in any way?
Not in the published record. Retatrutide acts on three incretin and glucagon receptors at the cell surface, and its weight effect has been attributed to reduced calorie intake alongside increased energy expenditure. 5-Amino-1MQ acts inside the cell on a methyltransferase, altering NAD+ salvage, methylation potential and polyamine flux, and the founding rodent work reported increased energy expenditure without a change in food intake. No paper has examined whether the two pathways interact, converge or oppose one another.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.